Company intelligence / Profile preview

PhilERA

Auckland, Auckland, New Zealand

Ownership: Private
Development stage: Other

Overview

PhilERA is a New Zealand-based biopharmaceutical company focused on developing novel copper-chelating therapies for the treatment of metabolic and rare diseases. Founded by the co-founders of Protemix Corporation, the company acquired Protemix's intellectual property assets out of liquidation to revive its therapeutic programs. PhilERA's lead research centers on triethylenetetramine (TETA) formulations, including triethylenetetramine disuccinate, a highly stable salt form of trientine with improved bioavailability. The company's pipeline targets copper-mediated oxidative stress to treat diabetic cardiomyopathy, diabetic nephropathy, and Wilson's disease.

Therapeutic areas: CardiovascularEndocrinologyNephrologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on PhilERA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PhilERA.

Explore the full profile